Since last month’s U.S.-Taliban peace plan, there have been nearly 80 attacks in Afghanistan. The violence could derail the deal that calls for U.S. troops to withdraw over the next 14 months.
You are here
Five years after an Ebola epidemic killed more than 11,000 people across West Africa, the U.S. Food and Drug Administration announced at the end of December 2019 that Merck, the behemoth, for-profit pharmaceutical company based in New Jersey, had received approval for an Ebola vaccine.
Consider a hypothetical corporation that has a monopoly over millions of people, providing a service that is indispensable to its customers. If it raises prices, customers have no choice but to pay those prices. Recognizing this, the government imposes some regulation. It cannot set arbitrarily high prices, but it negotiates with the government to obtain prices that guarantee a steady profit rate.
For the first time, scientists reviewed 26 types of per- and polyfluoroalkyl substances (PFAS) and found that they all display at least one characteristic of cancer-causing chemicals that can alter crucial bodily functions.
It’s true that the Trump administration signed a “peace deal” with the Taliban — something that eluded both George W. Bush and Barack Obama — but a closer look at the agreement reveals it to be riddled with conditions that are fraught with obstacles.